Evidence map›Paper›PMID 42387149›Full record

ArticleJournal of human genetics2026

Haplotype analysis of spinocerebellar ataxia type 36 suggests a shared permissive core haplotype across populations.

Katsuki Eguchi, Satoko Miyatake, Asako Takei, Hiroaki Yaguchi, Yuki Iida, Shinsuke Hamada, Yoshiko Ito, Sanae Honma, Fumio Moriwaka, Taishi Wada and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Katsuki EguchiHokuyukai Neurological Hospital, Sapporo, Japan. k198762@pop.med.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-2988-2532
Satoko MiyatakeDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-7587-5168
Asako TakeiHokuyukai Neurological Hospital, Sapporo, Japan.
Hiroaki YaguchiDepartment of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Yuki IidaHokuyukai Neurological Hospital, Sapporo, Japan.
Shinsuke HamadaHokuyukai Neurological Hospital, Sapporo, Japan.
Yoshiko ItoHokuyukai Neurological Hospital, Sapporo, Japan.
Sanae HonmaHokuyukai Neurological Hospital, Sapporo, Japan.
Fumio MoriwakaHokuyukai Neurological Hospital, Sapporo, Japan.
Taishi WadaDepartment of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Takashi JonoDepartment of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Misako KuniiDepartment of Neurology, Yokohama City University Medical Center, Yokohama, Japan.
Hiroyasu KomiyaDepartment of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Hitaru KishidaDepartment of Neurology, Yokohama Brain and Spine Center, Yokohama, Japan.
Hiroshi DoiDepartment of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-5807-2523
Fumiaki TanakaDepartment of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0002-9961-2693
Naomichi MatsumotoDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-9846-6500
Ichiro YabeDepartment of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. yabe@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-1734-7997

Funding

Japan Agency for Medical Research and Development (AMED) JP25ek0109674, JP25ek0109760, JP25ek0109617, JP25ek0109648, and JP25ek0109677MEXT | Japan Society for the Promotion of Science (JSPS) JP23K27520MEXT | Japan Society for the Promotion of Science (JSPS) JP24K02230
6 · The paper itself

Abstract

Spinocerebellar ataxia type 36 (SCA36)-caused by a GGCCTG hexanucleotide repeat expansion in the NOP56 gene-has traditionally been considered to originate from a founder effect in the Ashida River basin of southern Japan. However, its genetic background remains incompletely understood. In this study, we analyzed five Japanese patients with SCA36 from four unrelated families using long-read sequencing to determine repeat length and reconstruct detailed haplotypes around the NOP56 locus. We successfully resolved extended haplotypes ranging from approximately 90 kb to 1.3 Mb. All five individuals shared a 5.3-kb haplotype adjacent to the repeat expansion, while four patients from northern Japan shared a larger haplotype block of at least 95.2 kb. Comparison with seven previously reported Korean SCA36 cases revealed a shared 4.2-kb haplotype, and available data from other populations were concordant within a ~ 2.1-kb core region. Notably, the shared 5.3-kb haplotype is relatively common in the general population, suggesting that the underlying core haplotype may represent a permissive haplotypic background rather than a unique founder haplotype. These findings indicate that SCA36 is unlikely to be explained solely by a regional founder in southern Japan. Instead, a shared permissive haplotypic background may underlie repeat expansion, with large pathogenic expansion arising independently in different populations. This pattern may be consistent with a stepwise process of repeat expansion.

Indexed as

HaplotypesNuclear ProteinsSpinocerebellar AtaxiasDNA Repeat ExpansionFemaleFounder EffectHumansJapanMalePedigreeNOP56 protein, humanNuclear Proteins

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.